Results 91 to 100 of about 52,475 (270)

Characterizing Apixaban Pharmacokinetics Through Physiologically‐Based Pharmacokinetic Modeling: Critical Role of Biliary Secretion and Enterohepatic Circulation in Humans

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Apixaban, a factor Xa inhibitor, is a direct oral anticoagulant with a well‐balanced elimination; it is eliminated evenly via feces, urine (with no active secretion), and as metabolites after oral administration. The common understanding is that biliary secretion and enterohepatic circulation (EHC) of apixaban are limited in humans, and that ...
Toshiaki Tsuchitani   +3 more
wiley   +1 more source

The discovery of rivaroxaban: translating preclinical assessments into clinical practice

open access: yesFrontiers in Pharmacology, 2013
Direct oral anticoagulants that target a single coagulation factor (such as factor Xa or thrombin) have been developed in recent years in an attempt to address some of the limitations of traditional anticoagulants.
Dagmar eKubitza   +2 more
doaj   +1 more source

High INR on warfarin [PDF]

open access: yes, 2015
The bottom line Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes, and intake of alcohol and other drugs that may increase risk of bleeding or affect ...
Chevassut, Timothy J   +2 more
core   +1 more source

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial [PDF]

open access: gold, 2020
John Castle   +10 more
openalex   +1 more source

The incidence of serious complications after selective laser trabeculoplasty

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the incidence of serious complications after selective laser trabeculoplasty (SLT). Methods All patients who underwent SLT at the Department of Ophthalmology, Helsinki University Hospital, were eligible for the study from 1 January 2012 to 31 December 2018.
Eeva S. Ojanen   +2 more
wiley   +1 more source

PHC9 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN THE UK [PDF]

open access: yes, 2008
Vitis vinifera cell cultures respond to pathogens and elicitors by synthesizing and extracellularly accumulating stilbenoid phytoalexins. Large amounts of trans-resveratrol (t-R) are produced when a cell culture is elicited with methylated cyclodextrins (
Adrian   +81 more
core   +4 more sources

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

open access: yesBJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui   +2 more
wiley   +1 more source

Rivaroxaban-induced hemorrhage associated with ABCB1 genetic defect

open access: yesFrontiers in Pharmacology, 2016
We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, three months after switching anticoagulant from the vitamin K antagonist ...
Kuntheavy Ing Lorenzini   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy